BMY had a great earnings report on this undervalued stock, I did cut PFE shortly after entering it a few weeks ago to all-in on BMY as my pharmaceutical exposure. I believe this will be a great value play all year. My short-term target is still 55$, but 60$ is definitely in the cards as the price was way below fundamentals.